Objectives: Psoriasis is a chronic skin condition that can develop at any age. Childhood psoriasis can lead to stigmatization and reduced quality of life in children and parents. This study aimed to gather a detailed family-level understanding of the experience of childhood psoriasis during the time of transition to adolescence.
Design: A multi-perspectival interpretative phenomenological analysis (IPA) was used.
Methods: Sixteen semi-structured interviews with eight parent-child dyads were conducted and analysed in accordance with IPA principles.
Results: Three superordinate themes and three sub-themes were identified: 1. 'Transition and transaction' including: 1.1 'Shifting responsibilities and self-efficacy'; 2. 'Stigma and social impact'; and 3. 'The treatment journey' including: 3.1 'Finding an effective treatment', 3.2 'Coping with on-going management'. Uncertainties surrounding treatment options were an initial focus of difficulty for families. In adolescence, the difficulty shifted to be more identity focussed as the responsibility for disease management and the increased awareness on body image posed added challenges. Both parents and children described visibility and stigma as the most distressing aspects of living with psoriasis and experienced negative emotions that resurfaced during adolescence.
Conclusions: This study suggests that childhood psoriasis can have a significant impact on children, particularly as they begin to transition to adolescence. Findings also highlight the burden of psoriasis for parents. As such, psychological interventions (such as adapted forms of mindfulness-based Cognitive-Behavioural-Therapy) are needed to target and reduce stress. Such interventions are likely to require a systemic focus and support validation of the real impact and fear of stigmatization.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586832 | PMC |
http://dx.doi.org/10.1111/bjhp.12763 | DOI Listing |
Pediatr Rheumatol Online J
December 2024
Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Objective: This systematic search and review aimed to evaluate the available literature on discontinuation of adalimumab and other tumor necrosis factor inhibitors (TNFi) for patients with well-controlled chronic inflammatory arthritides.
Methods: We conducted a publication search on adalimumab discontinuation from 2000-2023 using PubMed, CINAHL, EMBASE, and Cochrane Library. Included studies evaluated adalimumab discontinuation approaches, tapering schemes, and outcomes including successful discontinuation and recapture after flare, in patients with well-controlled disease.
Heliyon
November 2024
Department of Applied Health Sciences, College of Medical and Dental Sciences, University of Birmingham, B152TT, UK.
Background: As a global public health issue, childhood maltreatment is associated with significant morbidity and mortality. We aimed to investigate the association between childhood maltreatment and immune-mediated inflammatory disorders (IMIDs).
Methods: We conducted a retrospective matched open cohort study using a UK primary care database between January 1, 1995 and January 31, 2021.
Dermatologie (Heidelb)
December 2024
Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Hauptstr. 7, 79104, Freiburg, Deutschland.
Oxf Med Case Reports
November 2024
Department of Dermatology, Tishreen University Hospital, Lattakia, Syria.
Rupioid psoriasis is a rare subtype of psoriasis characterized by distinctive lesions resembling oyster shells, known as rupioid lesions. This subtype is particularly uncommon in the pediatric population and is often associated with poor treatment compliance. Ustekinumab, an IgG monoclonal antibody, targets IL-12 and IL-23, reducing the release of proinflammatory cytokines TNFα, IL-2, and IL-17α, which play vital roles in psoriasis pathophysiology.
View Article and Find Full Text PDFJ Dermatol
November 2024
Department of Dermatology, Fukushima Medical University, Fukushima, Japan.
Erythroderma is the end-stage condition caused by various inflammatory diseases, presenting with widespread generalized coalesced erythema on the trunk and extremities. Erythroderma is not a disease itself, but rather is a symptom expressing erythrodermic condition, which is frequently associated with inguinal lymphadenopathy, chills, and mild fever. The clinical characteristics include sparing the folds of the trunk and extremities (deck-chair sign), and cobblestone-like disseminated grouping prurigo; however, the deck-chair sign is not specific to papulo-erythroderma (Ofuji disease).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!